Insmed Presents Positive IPLEX(TM) Data At ENDO 2006
27 Juin 2006 - 5:30PM
Business Wire
Insmed, Inc. (NASDAQ: INSM): Results from 3 IPLEX studies
demonstrate: -- IPLEX increases growth and improves blood sugar
control in patients with severe insulin-resistance syndromes, such
as Leprechaunism and Type A syndrome (1) -- IPLEX improves growth
rate in children with severe primary IGF-I deficiency(2) -- IPLEX
safely increases IGF-I levels in healthy adults without causing
abnormal increases in free IGF-I levels.(3) Insmed, Inc. (NASDAQ:
INSM) today announced new study results that show that IPLEX(TM)
(mecasermin rinfabate (rDNA origin) injection) is effective in
increasing growth and improving glycemic control in patients with
severe insulin-resistance syndromes, specifically Leprechaunism and
Type A syndrome. In another clinical trial, once-daily treatment
with IPLEX significantly improved height velocity in children with
severe primary insulin growth factor-I (IGF-I) deficiencies. A
third study of the pharmacokinetics of IPLEX in normal adults
showed positive results, with simultaneous increases in IGF-I and
IGFBP-3 and without undue increases in "free" IGF-I. Findings of
all three studies were presented this week at the annual meeting of
the Endocrine Society, ENDO 2006. In a study showing the impact of
IPLEX treatment on infants diagnosed with Leprechaunism (or Donohue
syndrome) (Abstract OR40-2), preliminary results indicate IPLEX
improved growth and glycemic (glucose) control, as well as
potentially prolonged the life of at least one patient.
Leprechaunism, the rarest and most severe insulin resistance
syndrome, is diagnosed in infancy and in some patients can result
in death in the first year of life. In this study, two patients
with Leprechaunism were treated with IPLEX. Results showed an
improved height standard deviation score in both patients (one from
-3.3 pre-treatment to -2.4 with treatment and the second from -2.8
pre-treatment to -1.8 with treatment). Additionally the first
patient achieved a reduction in HbA1c (7.6 percent pre-treatment to
6.7 percent with treatment), as well as a decrease in mean daily
glucose levels (9.4 mmol/L pre-treatment to 6.6 mmol/L with
treatment), indicating IPLEX produced a significant physiological
benefit in this patient. This patient has been on therapy for three
years and both patients currently remain on IPLEX treatment. In the
severe insulin resistance study, three adolescents with Type A
syndrome, a disease in which the patient exhibits poor glycemic
control despite conventional therapies, were evaluated on IPLEX
treatment. Each patient entered the trial with elevated glucose
levels and inadequate response to treatment with traditional
therapeutic agents. Results showed that these patients, when
treated with IPLEX, demonstrated approximately a 20% average
decrease in HbA1c and daily glucose levels. Patients receiving
IPLEX experienced decreased glucose excursions, reduced insulin
usage, and noticed less prominent acanthosis nigricans (dark,
velvety skin patches), which are commonly associated with severe
insulin resistance. In further evidence of drug-dependent changes,
all of these improvements worsened in each patient once IPLEX
treatment was terminated. "The preliminary results of this study
suggest that IPLEX can be more effective than conventional diabetes
therapies in patients with severe insulin resistance syndromes,"
said Kenneth M. Attie, M.D., Vice President, Medical Affairs,
Insmed. "We look forward to the completion of these studies with
IPLEX and continuing to evaluate its utility in diabetes-related
disorders, particularly in those with extreme insulin resistance."
Safety and Efficacy in Children with Severe Primary IGF-I
Deficiency A second study (Abstract OR 40-1) presented at ENDO
demonstrates IPLEX's safety and efficacy in children with severe
primary IGF-I deficiency. A prospective, multicenter clinical trial
of IPLEX administered once daily showed that treatment resulted in
statistically significant, dose-dependent increases in height
velocity (growth rate) with a favorable safety profile. Average
height velocity in one of the treatment groups, treated with a dose
of up to 2 mg/kg/day, increased from 2.0 cm/year pre-treatment to
8.3 cm/year during the first year of treatment. Children with
genetic and acquired forms of growth hormone (GH) insensitivity
appeared to respond equally well to treatment in this study. IPLEX
was generally well tolerated in these patients. Adverse events
included injection site reactions (including erythema,
lipohypertropy, and hair growth), hypoglycemia (generally rated as
mild and asymptomatic), headache, and tonsillar/adenoid
hypertrophy. IPLEX Pharmacokinetics in Normal Adults Presented
Results from a pharmacokinetic study of IPLEX, presented during 2
poster presentations, demonstrate that IPLEX has unique, positive
properties. The first poster (P1-191) presented the pharmacokinetic
results of single-dose administration of the drug to 28 healthy
adult volunteers. The investigators concluded that due to the
gradual absorption and elimination of IPLEX in the bloodstream,
sustained increases in levels of IGF-I and IGFBP-3 are achieved
lasting more than 24 hours. These data indicate that the drug can
be administered once-daily or, in certain patient populations,
possibly less frequently, such as every other day. IPLEX was well
tolerated during the study. A second poster from this study
(P1-192) examined the levels of free IGF-I in healthy adult
volunteers after administration of IPLEX. Under normal
circumstances, less than 2 percent of IGF-I circulates as the free
biologically active form because of a complex physiology that keeps
it bound to other proteins, principally IGFBP-3 and ALS. The IPLEX
complex was designed to limit the amount of free IGF-I associated
with replacement therapy, thus maintaining a physiological balance
of IGF-I with IGFBP-3. Results of this study conclude the mean
percent of free IGF-I did not exceed 1 percent at any time during
the 72-hour sampling period, thus avoiding supra-physiologic levels
of free IGF-I. "IPLEX was designed to provide IGF-I in a stable
complex with its natural binding protein, and thus mimic what
occurs naturally in human circulation," said Attie. "In the
pharmacokinetic study presented at ENDO, we demonstrated that the
drug limits the excursions of free IGF-I levels by providing a
gradual absorption of the apparently intact complex. The
pharmacokinetics of this drug make it an ideal treatment for
children with severe primary IGFD and, in the future, other patient
populations that might benefit from once daily IGF-I replacement."
About IPLEX IPLEX is approved in the United States as the only once
daily treatment for children with short stature associated with
severe primary IGF-I deficiency (Primary IGFD). IPLEX, a complex of
recombinant human IGF-I and its binding protein IGFBP-3
(rhIGF-I/rhIGFBP-3), is the only FDA-approved IGF-I replacement
therapy that also replaces deficient IGFBP-3 in these patients. The
drug, which was launched in the second quarter of 2006, is also
being investigated for various other indications with unmet medical
needs, including severe insulin resistance, myotonic muscular
dystrophy and HIV Associated Adipose Redistribution Syndrome
(HARS). For more information about IPLEX please go to
www.go-IPLEX.com. About Insmed Incorporated Insmed is a
biopharmaceutical company focused on the development and
commercialization of drug candidates for the treatment of metabolic
diseases and endocrine disorders with unmet medical needs. For more
information, please visit www.insmed.com. The Company's leading
product, IPLEX was approved as an orphan drug by the United States
Food and Drug Administration in December 2005 for the treatment of
growth failure in children with severe primary IGF-I deficiency
(Primary IGFD) or with growth hormone (GH) gene deletion who have
developed neutralizing antibodies to GH. Statements included within
this press release, which are not historical in nature, may
constitute forward-looking statements for purposes of the safe
harbor provided by the Private Securities Litigation Reform Act of
1995. Forward-looking statements in this press release include, but
are not limited to, statements regarding our IPLEX utilization
program, regulatory and business strategies, manufacturing
capabilities, product costs, plans and objectives of management and
growth opportunities for existing or proposed products. Such
forward-looking statements are subject to numerous risks and
uncertainties, including risks that product candidates may fail in
the clinic or may not be successfully launched, marketed,
manufactured or reimbursed, we may lack financial resources to
complete development of product candidates, the FDA may interpret
the results of our studies differently than we have, competing
products may be more successful, demand for new pharmaceutical
products may decrease, the biopharmaceutical industry may
experience negative market trends and other risks detailed from
time to time in our filings with the Securities and Exchange
Commission. As a result of these and other risks and uncertainties,
actual results may differ materially from those described in this
press release. For further information with respect to factors that
could cause actual results to differ from expectations, reference
is made to our reports filed by the Company with the Securities and
Exchange Commission under the Securities Exchange Act of 1934, as
amended. The forward-looking statements made in this release are
made only as of the date hereof and Insmed disclaims any intention
or responsibility for updating predictions or financial guidance
contained in this release. (1)ENDO 2006 Abstract OR40-2 -
rhIGF-1/rhIGFBP-3 Treatment of Patients with Severe Insulin
Resistance Syndromes: Preliminary Data. (2)ENDO 2006 Abstract
OR40-1 - Once Daily rhIGF-1/rhIGFBP-3 Treatment Improves Growth in
Children with Severe Primary IGF-I Deficiency: Results of a
Multicenter Clinical Trial (3)ENDO 2006 Abstract P1-192 -
Subcutaneous Administration of rhIGF-1/rhIGFBP-3 in Healthy Adult
Volunteers Does Not Result in Supraphysiological Concentrations of
Free IGF-I.
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024